This informative session, presented by Justin Botillier, CEO of Calyx CPA LLC, draws on sixteen years of experience working with small businesses and specific expertise in the cannabis and psychedelic industries. With the classification of psychedelics as Schedule I drugs, businesses in this sector are subject to 280E – a provision that often results in significant expenses. Justin was one of the first accountants to advocate for the cannabis industry and has since shifted his focus to the psychedelic community. His firm specializes in business advisory, entity formation, tax preparation, and tax planning for plant medicine companies. In this session, he will guide attendees through strategies to mitigate the impact of 280E, focusing on aggressive yet defensible tax positions that can help businesses navigate these unique tax challenges effectively and legally. This is an essential session for any business operating within the psilocybin industry.